Citations (78)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Emanuela Zappulo, Riccardo Scotto, Antonio Riccardo Buonomo, Alberto Enrico Maraolo, Biagio Pinchera & Ivan Gentile. (2020) Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment of Hepatitis C. Expert Opinion on Pharmacotherapy 21:3, pages 261-273.
Read now
Read now
Carol Stanciu, Anca Trifan, Cristina Muzica & Catalin Sfarti. (2019) Efficacy and safety of alisporivir for the treatment of hepatitis C infection. Expert Opinion on Pharmacotherapy 20:4, pages 379-384.
Read now
Read now
Praveen R. Juvvadi, Soo Chan Lee, Joseph Heitman & William J. Steinbach. (2017) Calcineurin in fungal virulence and drug resistance: Prospects for harnessing targeted inhibition of calcineurin for an antifungal therapeutic approach. Virulence 8:2, pages 186-197.
Read now
Read now
Ivan Gentile, Riccardo Scotto, Emanuela Zappulo, Antonio Riccardo Buonomo, Biagio Pinchera & Guglielmo Borgia. (2016) Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development. Expert Opinion on Investigational Drugs 25:5, pages 557-572.
Read now
Read now
Ivan Gentile, Emanuela Zappulo, Antonio Riccardo Buonomo, Riccardo Scotto & Guglielmo Borgia. (2015) Asunaprevir for hepatitis C: a safety evaluation. Expert Opinion on Drug Safety 14:10, pages 1631-1646.
Read now
Read now
Ivan Gentile, Emanuela Zappulo, Antonio Riccardo Buonomo, Alberto Enrico Maraolo & Guglielmo Borgia. (2015) Beclabuvir for the treatment of hepatitis C. Expert Opinion on Investigational Drugs 24:8, pages 1111-1121.
Read now
Read now
Ashley Arezou Minaei & Kris V Kowdley. (2015) ABT-450/ritonavir and ABT-267 in combination with ABT-333 for the treatment of hepatitis C virus. Expert Opinion on Pharmacotherapy 16:6, pages 929-937.
Read now
Read now
Sheng-Shun Yang & Jia-Horng Kao. (2015) Asunaprevir-containing regimens for the treatment of hepatitis C virus infection. Expert Review of Gastroenterology & Hepatology 9:1, pages 9-20.
Read now
Read now
Ivan Gentile, Antonio Riccardo Buonomo, Federico Borgia, Giuseppe Castaldo & Guglielmo Borgia. (2014)
Ledipasvir: a novel synthetic antiviral for the treatment of HCV infection. Expert Opinion on Investigational Drugs 23:4, pages 561-571.
Read now
Read now
Articles from other publishers (69)
Ayushi Chaurasiya, Geeta Kumari, Swati Garg, Rumaisha Shoaib, Zille Anam, Nishant Joshi, Jyoti Kumari, Jhalak Singhal, Niharika Singh, Shikha Kaushik, Amandeep Kaur Kahlon, Neha Dubey, Mukesh Kumar Maurya, Pallavi Srivastava, Manisha Marothia, Prerna Joshi, Kanika Gupta, Savita Saini, Gobardhan Das, Souvik Bhattacharjee, Shailja Singh & Anand Ranganathan. (2022) Targeting Artemisinin-Resistant Malaria by Repurposing the Anti-Hepatitis C Virus Drug Alisporivir. Antimicrobial Agents and Chemotherapy 66:12.
Crossref
Crossref
Robert Hromas, Gayathri Srinivasan, Ming Yang, Aruna Jaiswal, Taylor A. Totterdale, Linda Phillips, Austin Kirby, Nazli Khodayari, Mark Brantley, Elizabeth A. Williamson & Kimi Y. Kong. (2022) BRCA1 mediates protein homeostasis through the ubiquitination of PERK and IRE1. iScience 25:12, pages 105626.
Crossref
Crossref
Mohsen Akbarian, Ali Khani, Sara Eghbalpour & Vladimir N. Uversky. (2022) Bioactive Peptides: Synthesis, Sources, Applications, and Proposed Mechanisms of Action. International Journal of Molecular Sciences 23:3, pages 1445.
Crossref
Crossref
Silvia Parapini, Silvio Paone, Emanuela Erba, Loredana Cavicchini, Manoochehr Pourshaban, Francesco Celani, Alessandro Contini, Sarah D’Alessandro & Anna Olivieri. (2022)
In Vitro
Antimalarial Activity of Inhibitors of the Human GTPase Rac1
. Antimicrobial Agents and Chemotherapy 66:1.
Crossref
Crossref
Rosa Bellavita, Bruno Casciaro, Salvatore Di Maro, Diego Brancaccio, Alfonso Carotenuto, Annarita Falanga, Floriana Cappiello, Elisabetta Buommino, Stefania Galdiero, Ettore Novellino, Tom N. Grossmann, Maria Luisa Mangoni, Francesco Merlino & Paolo Grieco. (2021) First-in-Class Cyclic Temporin L Analogue: Design, Synthesis, and Antimicrobial Assessment. Journal of Medicinal Chemistry 64:15, pages 11675-11694.
Crossref
Crossref
Michael Bobardt, Christina M. Ramirez, Marc M. Baum, Daren Ure, Robert Foster & Philippe A. Gallay. (2021) The combination of the NS5A and cyclophilin inhibitors results in an additive anti-HCV inhibition in humanized mice without development of resistance. PLOS ONE 16:5, pages e0251934.
Crossref
Crossref
Jimin Xu, Yu Xue, Richard Zhou, Pei‐Yong Shi, Hongmin Li & Jia Zhou. (2020) Drug repurposing approach to combating coronavirus: Potential drugs and drug targets. Medicinal Research Reviews 41:3, pages 1375-1426.
Crossref
Crossref
G. V. Kochneva, M. Yu. Kartashov, E. I. Krivosheina, A. I. Kuznetsov, E. V. Chub, G. F. Sivolobova & S. V. Netesov. (2021) On the Possibility of Eradicating Hepatitis C in Russia. Molecular Genetics, Microbiology and Virology 36:1, pages 27-38.
Crossref
Crossref
G.V. Kochneva, M.Yu. Kartashov, E.I. Krivosheina, A.I. Kuznetsov, E.V. Chub, G.F. Sivolobova & S.V. Netesov. (2021) On the possibility of eradicating hepatitis C in Russia. Molecular Genetics Microbiology and Virology (Russian version) 39:1, pages 31.
Crossref
Crossref
N. Arul Murugan, K. Muruga Poopathi Raja & N. T. Saraswathi. 2021. Antiviral Drug Discovery and Development. Antiviral Drug Discovery and Development
261
284
.
Nicolas J. Scheuplein, Nicole M. Bzdyl, Emily A. Kibble, Theresa Lohr, Ulrike Holzgrabe & Mitali Sarkar-Tyson. (2020) Targeting Protein Folding: A Novel Approach for the Treatment of Pathogenic Bacteria. Journal of Medicinal Chemistry 63:22, pages 13355-13388.
Crossref
Crossref
Xiaoli Li, Jinhe Han, Hye Won Lee, Yi-Seul Yoon, Yifeng Jin, Daulat B. Khadka, Suhui Yang, Meehyein Kim & Won-Jea Cho. (2020) SAR study of bisamides as cyclophilin a inhibitors for the development of host-targeting therapy for hepatitis C virus infection. Bioorganic & Medicinal Chemistry 28:19, pages 115679.
Crossref
Crossref
Michael Bobardt, Magnus Joakim Hansson, Patrick Mayo, Daren Ure, Robert Foster & Philippe Gallay. (2020) Structurally distinct cyclosporin and sanglifehrin analogs CRV431 and NV556 suppress established HCV infection in humanized-liver mice. PLOS ONE 15:8, pages e0237236.
Crossref
Crossref
Runa S.J. Lindblom, Gavin C. Higgins, Tuong-Vi Nguyen, Maryann Arnstein, Darren C. Henstridge, Cesare Granata, Matthew Snelson, Vicki Thallas-Bonke, Mark E. Cooper, Josephine M. Forbes & Melinda T. Coughlan. (2020) Delineating a role for the mitochondrial permeability transition pore in diabetic kidney disease by targeting cyclophilin D. Clinical Science 134:2, pages 239-259.
Crossref
Crossref
Yue Ma-Lauer, Yu Zheng, Miroslav Malešević, Brigitte von Brunn, Gunter Fischer & Albrecht von Brunn. (2020) Influences of cyclosporin A and non-immunosuppressive derivatives on cellular cyclophilins and viral nucleocapsid protein during human coronavirus 229E replication. Antiviral Research 173, pages 104620.
Crossref
Crossref
D.J. Brayden, T.A. Hill, D.P. Fairlie, S. Maher & R.J. Mrsny. (2020) Systemic delivery of peptides by the oral route: Formulation and medicinal chemistry approaches. Advanced Drug Delivery Reviews 157, pages 2-36.
Crossref
Crossref
Philippe Gallay, Daren Ure, Michael Bobardt, Udayan Chatterji, James Ou, Daniel Trepanier & Robert Foster. (2019) The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice. PLOS ONE 14:6, pages e0217433.
Crossref
Crossref
Jatin Mehta & Chandi Charan Mandal. 2018. Apoptosis and Beyond. Apoptosis and Beyond
375
394
.
Eva Zusinaite, Aleksandr Ianevski, Diana Niukkanen, Minna Poranen, Magnar Bjørås, Jan Afset, Tanel Tenson, Vidya Velagapudi, Andres Merits & Denis Kainov. (2018) A Systems Approach to Study Immuno- and Neuro-Modulatory Properties of Antiviral Agents. Viruses 10:8, pages 423.
Crossref
Crossref
Carolin Zitzmann & Lars Kaderali. (2018) Mathematical Analysis of Viral Replication Dynamics and Antiviral Treatment Strategies: From Basic Models to Age-Based Multi-Scale Modeling. Frontiers in Microbiology 9.
Crossref
Crossref
Chao XueMark P. SowdenBradford C. Berk. (2018) Extracellular and Intracellular Cyclophilin A, Native and Post-Translationally Modified, Show Diverse and Specific Pathological Roles in Diseases. Arteriosclerosis, Thrombosis, and Vascular Biology 38:5, pages 986-993.
Crossref
Crossref
Rosella Scrima, Claudia Piccoli, Darius Moradpour & Nazzareno Capitanio. (2018) Targeting Endoplasmic Reticulum and/or Mitochondrial Ca2+ Fluxes as Therapeutic Strategy for HCV Infection. Frontiers in Chemistry 6.
Crossref
Crossref
Emilie Crouchet, Florian Wrensch, Catherine Schuster, Mirjam B. Zeisel & Thomas F. Baumert. (2018) Host-targeting therapies for hepatitis C virus infection: current developments and future applications. Therapeutic Advances in Gastroenterology 11, pages 175628481875948.
Crossref
Crossref
Michael W. Fried, Jama M. Darling & Stanley M. Lemon. 2017. Schiff's Diseases of the Liver. Schiff's Diseases of the Liver
628
698
.
Silvia Stotani & Fabrizio Giordanetto. 2017. Practical Medicinal Chemistry with Macrocycles. Practical Medicinal Chemistry with Macrocycles
411
499
.
Daniel S. Nielsen, Nicholas E. Shepherd, Weijun Xu, Andrew J. Lucke, Martin J. Stoermer & David P. Fairlie. (2017) Orally Absorbed Cyclic Peptides. Chemical Reviews 117:12, pages 8094-8128.
Crossref
Crossref
Edward Gane, Catherine Stedman, Kiran Dole, Jin Chen, Charles Daniel Meyers, Brigitte Wiedmann, Jin Zhang, Prakash Raman & Richard A. Colvin. (2016) A Diacylglycerol Transferase 1 Inhibitor Is a Potent Hepatitis C Antiviral in Vitro but Not in Patients in a Randomized Clinical Trial. ACS Infectious Diseases 3:2, pages 144-151.
Crossref
Crossref
Bianca Heinrich & John P. Bilello. 2017. Antimicrobial Drug Resistance. Antimicrobial Drug Resistance
579
609
.
Douglas D. Richman, Richard J. Whitley & Frederick J. HaydenMatthew L. Scherer, Chelsea Sammons, Brian Nelson, Scott M. Hammer & Elizabeth Verna. 2016. Clinical Virology. Clinical Virology
239
270
.
Lize Cuypers, Joke Snoeck, Lien Kerremans, Pieter Libin, Raf Crabbé, Sonia Van Dooren, Grégoire Vuagniaux & Anne-Mieke Vandamme. (2016) HCV1b genome evolution under selective pressure of the cyclophilin inhibitor alisporivir during the DEB-025-HCV-203 phase II clinical trial. Infection, Genetics and Evolution 44, pages 169-181.
Crossref
Crossref
Jae-Su Moon, Seung-Hoon Lee, Song-Hee Han, Eun-Jung Kim, Hee Cho, Wooseong Lee, Mi-Kyung Kim, Tae-Eun Kim, Hyun-Ji Park, Jin-Kyu Rhee, Seong-Jun Kim, Seung-Woo Cho, Seung Hyun Han & Jong-Won Oh. (2016) Inhibition of hepatitis C virus in mouse models by lipidoid nanoparticle-mediated systemic delivery of siRNA against PRK2. Nanomedicine: Nanotechnology, Biology and Medicine 12:6, pages 1489-1498.
Crossref
Crossref
Udayan Chatterji, Michael Bobardt, Lana Schaffer, Malcolm Wood & Philippe A. Gallay. (2016) Cyclophilin Inhibitors Remodel the Endoplasmic Reticulum of HCV-Infected Cells in a Unique Pattern Rendering Cells Impervious to a Reinfection. PLOS ONE 11:7, pages e0159511.
Crossref
Crossref
Annalaura BraiRoberta FaziCristina TintoriClaudio ZamperiniFrancesca BugliMaurizio SanguinettiEgidio StiglianoJosé EstéRoger BadiaSandra FrancoMiguel A. Martinez, Javier P. MartinezAndreas MeyerhansFrancesco SaladiniMaurizio ZazziAnna GarbelliGiovanni Maga & Maurizio Botta. (2016) Human DDX3 protein is a valuable target to develop broad spectrum antiviral agents. Proceedings of the National Academy of Sciences 113:19, pages 5388-5393.
Crossref
Crossref
Justin Warne, Gareth Pryce, Julia M. Hill, Xiao Shi, Felicia Lennerås, Fabiola Puentes, Maarten Kip, Laura Hilditch, Paul Walker, Michela I. Simone, A.W. Edit. Chan, Greg J. Towers, Alun R. Coker, Michael R. Duchen, Gyorgy Szabadkai, David Baker & David L. Selwood. (2016) Selective Inhibition of the Mitochondrial Permeability Transition Pore Protects against Neurodegeneration in Experimental Multiple Sclerosis. Journal of Biological Chemistry 291:9, pages 4356-4373.
Crossref
Crossref
Naba Saeed. (2017) Tackling HCV-3 in Asia: Breakthroughs for Efficient and
Cost-effective Treatment Strategies. Euroasian Journal of Hepato-Gastroenterology 6:1, pages 35-42.
Crossref
Crossref
S. Zeuzem, R. Flisiak, J. M. Vierling, W. Mazur, G. Mazzella, S. Thongsawat, D. Abdurakhmanov, N. Van Kính, P. Calistru, J. Heo, C. Stanciu, M. Gould, M. Makara, S.-J. Hsu, P. Buggisch, D. Samuel, D. Mutimer, B. Nault, M. Merz, W. Bao, L. H. Griffel, C. Brass & N. V. Naoumov. (2015) Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II). Alimentary Pharmacology & Therapeutics 42:7, pages 829-844.
Crossref
Crossref
Tokiko Watanabe & Yoshihiro Kawaoka. (2015) Influenza virus–host interactomes as a basis for antiviral drug development. Current Opinion in Virology 14, pages 71-78.
Crossref
Crossref
Sam Hopkins & Philippe A. Gallay. (2015) The role of immunophilins in viral infection. Biochimica et Biophysica Acta (BBA) - General Subjects 1850:10, pages 2103-2110.
Crossref
Crossref
You Li, Daisuke Yamane, Takahiro Masaki & Stanley M. Lemon. (2015) The yin and yang of hepatitis C: synthesis and decay of hepatitis C virus RNA. Nature Reviews Microbiology 13:9, pages 544-558.
Crossref
Crossref
M. Buti, R. Flisiak, J.-H. Kao, W.-L. Chuang, A. Streinu-Cercel, F. Tabak, P. Calistru, T. Goeser, J. Rasenack, A. Horban, G. L. Davis, A. Alberti, G. Mazzella, S. Pol, R. Orsenigo & C. Brass. (2015) Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial. Journal of Viral Hepatitis 22:7, pages 596-606.
Crossref
Crossref
Marie Dujardin, Vanesa Madan, Roland Montserret, Puneet Ahuja, Isabelle Huvent, Helene Launay, Arnaud Leroy, Ralf Bartenschlager, François Penin, Guy Lippens & Xavier Hanoulle. (2015) A Proline-Tryptophan Turn in the Intrinsically Disordered Domain 2 of NS5A Protein Is Essential for Hepatitis C Virus RNA Replication. Journal of Biological Chemistry 290:31, pages 19104-19120.
Crossref
Crossref
Udayan Chatterji, Michael Bobardt, Andrew Tai, Malcolm Wood & Philippe A. Gallay. (2015) Cyclophilin and NS5A Inhibitors, but Not Other Anti-Hepatitis C Virus (HCV) Agents, Preclude HCV-Mediated Formation of Double-Membrane-Vesicle Viral Factories. Antimicrobial Agents and Chemotherapy 59:5, pages 2496-2507.
Crossref
Crossref
Sandra Phillips, Shilpa Chokshi, Udayan Chatterji, Antonio Riva, Michael Bobardt, Roger Williams, Philippe Gallay & Nikolai V. Naoumov. (2015) Alisporivir Inhibition of Hepatocyte Cyclophilins Reduces HBV Replication and Hepatitis B Surface Antigen Production. Gastroenterology 148:2, pages 403-414.e7.
Crossref
Crossref
Patrick T. Dolan, Andrew P. Roth, Bin Xue, Ren Sun, A. Keith Dunker, Vladimir N. Uversky & Douglas J. LaCount. (2015) Intrinsic disorder mediates hepatitis C virus core-host cell protein interactions. Protein Science 24:2, pages 221-235.
Crossref
Crossref
Søren Ottosen, Todd B. Parsley, Lu Yang, Karin Zeh, Leen-Jan van Doorn, Eva van der Veer, Anneke K. Raney, Michael R. Hodges & Amy K. Patick. (2015)
In Vitro
Antiviral Activity and Preclinical and Clinical Resistance Profile of Miravirsen, a Novel Anti-Hepatitis C Virus Therapeutic Targeting the Human Factor miR-122
. Antimicrobial Agents and Chemotherapy 59:1, pages 599-608.
Crossref
Crossref
Patrick Arbuthnot. 2015. Gene Therapy for Viral Infections. Gene Therapy for Viral Infections
191
226
.
Avantika Barve, Steven J. Kovacs, June Ke, Rafael Crabbe, Peter Grosgurin, Annick Menetrey, Valerie Nicolas-Métral, Kristina Dabovic, Kiran Dole, Jie Zhang, Jens Praestgaard, Gangadhar Sunkara & Daniel Stein. (2015) The effects of CYP3A4 induction and inhibition on the pharmacokinetics of alisporivir in humans. Clinical Pharmacology in Drug Development 4:1, pages 25-32.
Crossref
Crossref
Moheshwarnath Issur & Matthias Götte. (2014) Resistance Patterns Associated with HCV NS5A Inhibitors Provide Limited Insight into Drug Binding. Viruses 6:11, pages 4227-4241.
Crossref
Crossref
Nicholas S Eyre, Karla J Helbig & Michael R Beard. (2014) Current and future targets of antiviral therapy in the hepatitis C virus life cycle. Future Virology 9:11, pages 947-965.
Crossref
Crossref
T H T Nguyen, F Mentré, M Levi, J Yu & J Guedj. (2014) A Pharmacokinetic–Viral Kinetic Model Describes the Effect of Alisporivir as Monotherapy or in Combination With Peg-IFN on Hepatitis C Virologic Response. Clinical Pharmacology & Therapeutics 96:5, pages 599-608.
Crossref
Crossref
Nikolai V. Naoumov. (2014) Cyclophilin inhibition as potential therapy for liver diseases. Journal of Hepatology 61:5, pages 1166-1174.
Crossref
Crossref
Fabrizio Giordanetto, Anja Schäfer & Christian Ottmann. (2014) Stabilization of protein–protein interactions by small molecules. Drug Discovery Today 19:11, pages 1812-1821.
Crossref
Crossref
Jiping Fu, Meiliana Tjandra, Christopher Becker, Dallas Bednarczyk, Michael Capparelli, Robert Elling, Imad Hanna, Roger Fujimoto, Markus Furegati, Subramanian Karur, Theresa Kasprzyk, Mark Knapp, Kwan Leung, Xiaolin Li, Peichao Lu, Wosenu Mergo, Charlotte Miault, Simon Ng, David Parker, Yunshan Peng, Silvio Roggo, Alexey Rivkin, Robert L. Simmons, Michael Wang, Brigitte Wiedmann, Andrew H. Weiss, Linda Xiao, Lili Xie, Wenjian Xu, Aregahegn Yifru, Shengtian Yang, Bo Zhou & Zachary K. Sweeney. (2014) Potent Nonimmunosuppressive Cyclophilin Inhibitors With Improved Pharmaceutical Properties and Decreased Transporter Inhibition. Journal of Medicinal Chemistry 57:20, pages 8503-8516.
Crossref
Crossref
Francesco Azzaroli, Marco Montagnani, Alberto Porro, Domenico Fiorillo & Giuseppe Mazzella. (2014) The future of dual therapy for hepatitis C virus. Future Virology 9:10, pages 905-912.
Crossref
Crossref
Benoît de Chassey, Laurène Meyniel-Schicklin, Jacky Vonderscher, Patrice André & Vincent Lotteau. (2014) Virus-host interactomics: new insights and opportunities for antiviral drug discovery. Genome Medicine 6:11.
Crossref
Crossref
Phillip C. Delekta, Craig J. Dobry, Janice A. Sindac, Scott J. Barraza, Pennelope K. Blakely, Jianming Xiang, Paul D. Kirchhoff, Richard F. Keep, David N. Irani, Scott D. Larsen & David J. Miller. (2014)
Novel Indole-2-Carboxamide Compounds Are Potent Broad-Spectrum Antivirals Active against Western Equine Encephalitis Virus
In Vivo
. Journal of Virology 88:19, pages 11199-11214.
Crossref
Crossref
Zachary K. Sweeney, Jiping Fu & Brigitte Wiedmann. (2014) From Chemical Tools to Clinical Medicines: Nonimmunosuppressive Cyclophilin Inhibitors Derived from the Cyclosporin and Sanglifehrin Scaffolds. Journal of Medicinal Chemistry 57:17, pages 7145-7159.
Crossref
Crossref
Udayan Chatterji, Jose A. Garcia-Rivera, James Baugh, Katarzyna Gawlik, Kelly A. Wong, Weidong Zhong, Clifford A. Brass, Nikolai V. Naoumov & Philippe A. Gallay. (2014) The Combination of Alisporivir plus an NS5A Inhibitor Provides Additive to Synergistic Anti-Hepatitis C Virus Activity without Detectable Cross-Resistance. Antimicrobial Agents and Chemotherapy 58:6, pages 3327-3334.
Crossref
Crossref
Erik De Clercq. (2014) Current race in the development of DAAs (direct-acting antivirals) against HCV. Biochemical Pharmacology 89:4, pages 441-452.
Crossref
Crossref
Vineela Chukkapalli & Glenn Randall. (2014) Hepatitis C Virus Replication Compartment Formation: Mechanism and Drug Target. Gastroenterology 146:5, pages 1164-1167.
Crossref
Crossref
Javier Carbajo-Lozoya, Yue Ma-Lauer, Miroslav Malešević, Martin Theuerkorn, Viktoria Kahlert, Erik Prell, Brigitte von Brunn, Doreen Muth, Thomas F. Baumert, Christian Drosten, Gunter Fischer & Albrecht von Brunn. (2014) Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir. Virus Research 184, pages 44-53.
Crossref
Crossref
Jeremie Guedj, Jing Yu, Micha Levi, Bin Li, Steven Kern, Nikolai V. Naoumov & Alan S. Perelson. (2014) Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patients. Hepatology 59:5, pages 1706-1714.
Crossref
Crossref
Heidi J. Einolf & Imad Hanna. 2014. Predictive ADMET. Predictive ADMET
353
396
.
Makonen Belema, Omar D. Lopez, John A. Bender, Jeffrey L. Romine, Denis R. St. Laurent, David R. Langley, Julie A. Lemm, Donald R. O’BoyleIIII, Jin-Hua Sun, Chunfu Wang, Robert A. Fridell & Nicholas A. Meanwell. (2014) Discovery and Development of Hepatitis C Virus NS5A Replication Complex Inhibitors. Journal of Medicinal Chemistry 57:5, pages 1643-1672.
Crossref
Crossref
Daniele Serranti, Giuseppe Indolfi & Massimo Resti. (2014) New treatments for chronic hepatitis C: An overview for paediatricians. World Journal of Gastroenterology 20:43, pages 15965.
Crossref
Crossref
T.R. Lim, B.H. Tan & D.J. Mutimer. (2014) Evolution and emergence of a new era of antiviral treatment for chronic hepatitis C infection. International Journal of Antimicrobial Agents 43:1, pages 17-25.
Crossref
Crossref
James M. Baugh, Jose A. Garcia-Rivera & Philippe A. Gallay. (2013) Host-targeting agents in the treatment of hepatitis C: A beginning and an end?. Antiviral Research 100:2, pages 555-561.
Crossref
Crossref
Hilde M. van der Schaar, Pieter Leyssen, Hendrik J. Thibaut, Armando de Palma, Lonneke van der Linden, Kjerstin H. W. Lanke, Céline Lacroix, Erik Verbeken, Katja Conrath, Angus M. MacLeod, Dale R. Mitchell, Nicholas J. Palmer, Hervé van de Poël, Martin Andrews, Johan Neyts & Frank J. M. van Kuppeveld. (2013) A Novel, Broad-Spectrum Inhibitor of Enterovirus Replication That Targets Host Cell Factor Phosphatidylinositol 4-Kinase IIIβ. Antimicrobial Agents and Chemotherapy 57:10, pages 4971-4981.
Crossref
Crossref
Gunter Fischer & Miroslav Malešević. 2001. eLS. eLS.